0.19
+0.014(+7.78%)
Currency In USD
Address
2 Executive Campus
Cherry Hill, NJ 08002
United States of America
Phone
201 479 1357
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
April 01, 2021
| Name | Title | Pay | Year Born |
| Mr. Andrew D.C. LaFrence C.P.A., CPA | Pres, Chief Executive Officer & Chief Financial Officer | 407,400 | 1963 |
| Mr. Andrew D.C. LaFrence CPA | President, Chief Executive Officer & Chief Financial Officer | 407,400 | 1963 |
| Mr. Andrew D.C. LaFrence CPA, CPA | Pres, Chief Executive Officer & Chief Financial Officer | 407,400 | 1963 |
| Mr. John A. Roberts M.B.A., MBA | Pres, Chief Executive Officer & Director | 597,692 | 1959 |
| Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P. | Co-Founder & Director | 22,500 | 1976 |
| Dr. Robert J. Petcavich Ph.D. | Chief Science Advisor & Director | 0 | 1954 |
| Dr. Robert Thomas Fremeau Jr., Ph.D. | Chief Scientific Officer | 0 | 1955 |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.